[1] Savarese, G. & Lund, L. H. Global Public Health Burden of Heart Failure. Cardiac failure review 3, 7-11, doi:10.15420/cfr.2016:25:2 (2017).
[2] Mamas, M. A. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European journal of heart failure 19, 1095-1104, doi:10.1002/ejhf.822 (2017).
[3] Deutscher Herzbericht 2021. https://www.herzstiftung.de/system/files/2022-09/DHB21-Herzbericht-2021.pdf.
[4] Arand, M. Chronische Herzinsuffizienz: Bilanz nach einem Jahr mit ARNI. Dtsch Arztebl International 113, A-2174 (2016).
[5] McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42, 3599-3726, doi:10.1093/eurheartj/ehab368 (2021).
[6] McMurray, J. J. V. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381, 1995-2008, doi:10.1056/NEJMoa1911303 (2019).
[7] Fachinformation Forxiga®, Stand Februar 2023.
[8] Berg, D. D. et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, doi:10.1001/jamacardio.2020.7585 (2021).
[9] Packer, M. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 383, 1413-1424, doi:10.1056/NEJMoa2022190 (2020).
[10] McMurray, J. J. V. & Packer, M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. Circulation, doi:10.1161/circulationaha.120.052926 (2020).
[11] Berliner, D., Hänselmann, A. & Bauersachs, J. Therapie der Herzinsuffizienz mit reduzierter Ejektionsfraktion. Dtsch Arztebl International 117, 376-385 (2020).
[12] Greene, S. J. et al. The vulnerable phase after hospitalization for heart failure. Nature reviews. Cardiology 12, 220-229, doi:10.1038/nrcardio.2015.14 (2015).
[13] Soltani, S. et al. [A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction]. Dtsch Med Wochenschr 147, 931-938, doi:10.1055/a-1760-3843 (2022).
[14] Khan, M. S., Butler, J. & Greene, S. J. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. Circulation. Heart failure 13, e008030, doi:10.1161/circheartfailure.120.008030 (2020).
[15] Heerspink, H. J. L. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383, 1436-1446, doi:10.1056/NEJMoa2024816 (2020).
[16] Jhund, P. S. et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28, 1956-1964, doi:10.1038/s41591-022-01971-4 (2022).
